Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Mar 2011Cited by 246 (Europe PMC)

PMID20814967DOI10.1002/jbmr.238PepBankPUB-20814967

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased lumbar spine BMD more than zoledronic acid at week 52.
In plain wordsIn women with osteoporosis, teriparatide increased spine bone density more than zoledronic acid at week 52.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at week 52
Study
n: not reported in source
Comparator
Zoledronic acid alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Lumbar spine BMD increase
7%
teriparatide
Lumbar spine BMD increase
4.4%
zoledronic acid
Source sentences
Summary
At week 52, lumbar spine BMD had increased 7.5%, 7.0%, and 4.4% in the combination, teriparatide, and zoledronic acid groups, respectively (p < .001 for combination and teriparatide versus zoledronic acid).
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496701
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, adding teriparatide to zoledronic acid increased lumbar spine BMD more than zoledronic acid alone.
In plain wordsIn women with osteoporosis, adding teriparatide to zoledronic acid increased spine bone density more than zoledronic acid alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombination lumbar spine BMD at week 52
Study
n: not reported in source
Comparator
Zoledronic acid alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Lumbar spine BMD increase
7.5%
combination
Lumbar spine BMD increase
4.4%
zoledronic acid
Source sentences
Summary
At week 52, lumbar spine BMD had increased 7.5%, 7.0%, and 4.4% in the combination, teriparatide, and zoledronic acid groups, respectively (p < .001 for combination and teriparatide versus zoledronic acid).
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496702
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, adding teriparatide to zoledronic acid increased spine BMD faster at 13 and 26 weeks.
In plain wordsIn women with osteoporosis, adding teriparatide increased spine bone density faster than zoledronic acid alone at 13 and 26 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEarly combination spine BMD versus zoledronic acid
Study
n: not reported in source
Comparator
Zoledronic acid alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
In the combination group, spine BMD increased more rapidly than with either agent alone (p < .001 versus both teriparatide and zoledronic acid at 13 and 26 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496704
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, adding teriparatide to zoledronic acid increased total hip BMD more than zoledronic acid alone at 13 weeks.
In plain wordsIn women with osteoporosis, adding teriparatide increased hip bone density more than zoledronic acid alone at 13 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD at 13 weeks, combination versus zoledronic acid
Study
n: not reported in source
Comparator
Zoledronic acid alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
Combination therapy increased total-hip BMD more than teriparatide alone at all times (all p < .01) and more than zoledronic acid at 13 weeks (p < .05), with final 52-week increments of 2.3%, 1.1%, and 2.2% in the combination, teriparatide, and zoledronic acid groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496706
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, total hip BMD increased 1.1% from baseline after 52 weeks of teriparatide.
In plain wordsIn women with osteoporosis, hip bone density increased 1.1% from baseline after 52 weeks of teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTeriparatide total hip BMD change
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Total hip BMD increase
1.1%
teriparatide at 52 weeks
Source sentences
Summary
Combination therapy increased total-hip BMD more than teriparatide alone at all times (all p < .01) and more than zoledronic acid at 13 weeks (p < .05), with final 52-week increments of 2.3%, 1.1%, and 2.2% in the combination, teriparatide, and zoledronic acid groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496707
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, early β-CTX reduction with zoledronic acid plus teriparatide had similar magnitude to zoledronic acid alone.
In plain wordsIn women with osteoporosis, early β-CTX reduction was similar with zoledronic acid plus teriparatide and zoledronic acid alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEarly combination β-CTX versus zoledronic acid
Study
n: not reported in source
Comparator
Zoledronic acid alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
Bone resorption (assessed by serum β-C-telopeptide of type I collagen [β-CTX]) was markedly reduced with combination therapy from 0 to 8 weeks (a reduction of similar magnitude to that seen with zoledronic acid alone), followed by a gradual increase after week 8, with levels remaining above baseline…
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
Report a problemFND-2081496710

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, zoledronic acid plus teriparatide increased spine BMD faster than teriparatide alone at 13 and 26 weeks.
In plain wordsIn women with osteoporosis, zoledronic acid plus teriparatide increased spine bone density faster than teriparatide alone at 13 and 26 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEarly combination spine BMD versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the combination group, spine BMD increased more rapidly than with either agent alone (p < .001 versus both teriparatide and zoledronic acid at 13 and 26 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496703
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, zoledronic acid plus teriparatide increased total hip BMD more than teriparatide alone at all measured times.
In plain wordsIn women with osteoporosis, zoledronic acid plus teriparatide increased hip bone density more than teriparatide alone at all measured times.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombination total hip BMD versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD increase
2.3%
combination at 52 weeks
Total hip BMD increase
1.1%
teriparatide at 52 weeks
Source sentences
Summary
Combination therapy increased total-hip BMD more than teriparatide alone at all times (all p < .01) and more than zoledronic acid at 13 weeks (p < .05), with final 52-week increments of 2.3%, 1.1%, and 2.2% in the combination, teriparatide, and zoledronic acid groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496705
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, zoledronic acid plus teriparatide produced an initial PINP rise, a minimal decline, then sustained increases above baseline.
In plain wordsIn women with osteoporosis, PINP initially rose, declined slightly, then rose again during zoledronic acid plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedCombination PINP time course
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With combination therapy, bone formation (assessed by serum N-terminal propeptide of type I collagen [PINP]) increased from 0 to 4 weeks, declined minimally from 4 to 8 weeks, and then rose throughout the trial, with levels above baseline from 6 to 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496708
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, zoledronic acid plus teriparatide initially reduced β-CTX, which later increased above baseline during the latter half-year.
In plain wordsIn women with osteoporosis, β-CTX initially fell, then rose above baseline during zoledronic acid plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedCombination β-CTX time course
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Bone resorption (assessed by serum β-C-telopeptide of type I collagen [β-CTX]) was markedly reduced with combination therapy from 0 to 8 weeks (a reduction of similar magnitude to that seen with zoledronic acid alone), followed by a gradual increase after week 8, with levels remaining above baseline…
1 context sentence(design, population, supporting numbers)
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496709
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, PINP levels were significantly lower with zoledronic acid plus teriparatide than teriparatide alone.
In plain wordsIn women with osteoporosis, PINP levels were lower with zoledronic acid plus teriparatide than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCombination PINP versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Levels for both markers were significantly lower with combination therapy versus teriparatide alone (p < .002).
2 context sentences(design, population, supporting numbers)
Summary · context
With combination therapy, bone formation (assessed by serum N-terminal propeptide of type I collagen [PINP]) increased from 0 to 4 weeks, declined minimally from 4 to 8 weeks, and then rose throughout the trial, with levels above baseline from 6 to 12 months.
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496711
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, β-CTX levels were significantly lower with zoledronic acid plus teriparatide than teriparatide alone.
In plain wordsIn women with osteoporosis, β-CTX levels were lower with zoledronic acid plus teriparatide than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCombination β-CTX versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Levels for both markers were significantly lower with combination therapy versus teriparatide alone (p < .002).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone resorption (assessed by serum β-C-telopeptide of type I collagen [β-CTX]) was markedly reduced with combination therapy from 0 to 8 weeks (a reduction of similar magnitude to that seen with zoledronic acid alone), followed by a gradual increase after week 8, with levels remaining above baseline…
Summary · context
412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2081496712

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01750086

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Massachusetts General Hospitaln = 27Jan 2013 to Aug 2014

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 27 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.